Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.100
+0.020 (1.85%)
At close: Apr 28, 2026, 4:00 PM EDT
1.100
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Alzamend Neuro Employees
As of April 30, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,257,455
Market Cap
4.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| VivoSim Labs | 14 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| 60 Degrees Pharmaceuticals | 3 |
ALZN News
- 21 days ago - Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - PRNewsWire
- 4 weeks ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 6 weeks ago - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - PRNewsWire
- 5 months ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire
- 9 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 9 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 11 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 11 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire